Trial Profile

An Open-label, Single-arm Study Evaluated the Efficacy and Safety of JS002 in Patients With Homozygous Familial Hypercholesterolemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ongericimab (Primary)
Indications Hyperlipoproteinaemia type IIa
Focus Registrational; Therapeutic Use
Sponsors Shanghai Junshi Biosciences

Most Recent Events

24 Jul 2024 Status changed from active, no longer recruiting to completed.
25 Apr 2023 According to a Junshi Biosciences - Impact Therapeutics (JV) media release, the National Medical Products Administration has accepted the new drug application for JS002. new drug application is mainly based on three registered clinical trials (JS002-003, JS002-004 and JS002-006).
07 Nov 2022 Primary endpoint (The primary endpoint of effectiveness) has been met according to results presented at the American Heart Association Scientific Sessions 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com